Tumors need a blood supply in order to grow and spread. The development of these blood vessels is called angiogenesis. One way of controlling cancer is to inhibit angiogenesis.
MEDI3617 is an antibody (a type of protein that is part of the immune system) which binds to proteins involved in angiogenesis called angiopoietin 1 and angiopoietin 2. Laboratory studies suggest that MEDI3617 can inhibit new blood vessel formation in tumors, thereby “starving” the tumor of the nutrients and oxygen it requires to continue to grow.
In this study, researchers want to find the highest dose of MEDI3617 that can be given safely in patients with advanced solid tumors that continue to grow despite standard therapy or for which no standard therapy exists. This is the “dose-escalation” part of the study. In a second part of the study, MEDI3617 will be evaluated specifically in patients with advanced non-small cell lung cancer or advanced colorectal cancer that continues to grow despite therapy.